What prices did the Faeth Therapeutics (FTH) CEO pay for the recent share acquisitions?

For the option exercises, Anand Kiran Parikh acquired 53,465 Faeth Therapeutics shares at an exercise price of $1.16 per share. Separately, he bought 2,806 shares in the open market at $19.76 per share on June 22, 2026.

Is the Faeth Therapeutics (FTH) CEO’s Form 4 related to any corrections or amendments?

Yes. A footnote explains a prior Form 4/A had a clerical error in an option expiration date. This Form 4 corrects that date to December 1, 2035, while leaving all other previously reported information unchanged.

Faeth Therapeutics (FTH) CEO buys shares and exercises stock options

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Faeth Therapeutics, Inc. President and CEO Anand Kiran Parikh increased his direct stake through option exercises and an open-market stock purchase. He exercised employee stock options to acquire 53,465 shares of common stock at $1.16 per share and bought an additional 2,806 shares in the open market at $19.76 per share, all on June 22, 2026. Following these transactions, he directly owns 764,234 shares of Faeth Therapeutics common stock.

Insider Trade Summary

Net Buyer: 2,806 shares ($55,447)

Net Buy 5 txns

Insider Parikh Anand Kiran

Role President and CEO

Bought 2,806 shs ($55K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	45,252	$0.00	--
Exercise	Employee Stock Option (right to buy)	8,213	$0.00	--
Purchase	Common Stock	2,806	$19.76	$55K
Exercise	Common Stock	45,252	$1.16	$52K
Exercise	Common Stock	8,213	$1.16	$10K

Holdings After Transaction: Employee Stock Option (right to buy) — 91,632 shares (Direct, null); Common Stock — 764,234 shares (Direct, null)

Footnotes (1)

Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027. The Form 4/A filed on June 16, 2026 (the "Form 4/A") contained a clerical error with respect to the expiration date of the reported security. This Form 4 corrects that clerical error to report the expiration date of the reported security as December 1, 2035. All other information reported on the Form 4/A remains unchanged. Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

Key Figures

Option shares exercised: 53,465 shares Option exercise price: $1.16 per share Open-market shares bought: 2,806 shares +4 more

7 metrics

Option shares exercised 53,465 shares Employee stock options exercised on June 22, 2026

Option exercise price $1.16 per share Exercise price for 53,465 common shares

Open-market shares bought 2,806 shares Common stock purchase on June 22, 2026

Open-market purchase price $19.76 per share Price paid for 2,806 common shares

Shares owned after transactions 764,234 shares Direct common stock holding after June 22, 2026

Net buy-sell shares 2,806 shares Net open-market activity reported as net-buy

Option expiration date (corrected) December 1, 2035 Corrected expiration date for reported option

Key Terms

open-market purchase, Employee Stock Option (right to buy), Exercise or conversion of derivative security, vest monthly, +2 more

6 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

vest monthly financial

"Beginning on March 1, 2026, 12,258 shares vest monthly"

clerical error financial

"contained a clerical error with respect to the expiration date"

monthly installments financial

"shares subject to the option vest in a series of forty-eight successive equal monthly installments"

Monthly installments are regular, fixed payments made each month to gradually pay off a larger amount, such as a loan or purchase. Think of it like paying for a big item in small, manageable parts instead of all at once. For investors, understanding installment payments helps gauge how debts are structured and how they might affect financial stability or cash flow over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 06:55 PM Accepted by SEC EDGAR 06/24/2026 - 06:55 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parikh Anand Kiran

(Last)

(First)

(Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN

TEXAS

78702

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Faeth Therapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/22/2026		P		2,806	A	$19.76	764,234	D
Common Stock	06/22/2026		M		45,252	A	$1.16	809,486	D
Common Stock	06/22/2026		M		8,213	A	$1.16	817,699	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$1.16	06/22/2026		M			45,252	⁽¹⁾	12/01/2035⁽²⁾	Common Stock	45,252	$0	91,632	D
Employee Stock Option (right to buy)	$1.16	06/22/2026		M			8,213	⁽³⁾	09/14/2032	Common Stock	8,213	$0	4,107	D

Explanation of Responses:

1. Beginning on March 1, 2026, 12,258 shares vest monthly through January 1, 2027, with the balance fully vesting on February 1, 2027.

2. The Form 4/A filed on June 16, 2026 (the "Form 4/A") contained a clerical error with respect to the expiration date of the reported security. This Form 4 corrects that clerical error to report the expiration date of the reported security as December 1, 2035. All other information reported on the Form 4/A remains unchanged.

3. Beginning August 1, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.

	/s/ Josiah Craver, Attorney-in-Fact	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Faeth Therapeutics (FTH) CEO Anand Kiran Parikh do in this Form 4?

Anand Kiran Parikh increased his direct holdings by exercising stock options for 53,465 shares at $1.16 and purchasing 2,806 shares at $19.76. All transactions involved Faeth Therapeutics common stock on June 22, 2026.

How many Faeth Therapeutics (FTH) shares does the CEO own after these transactions?

After the reported transactions, Anand Kiran Parikh directly owns 764,234 shares of Faeth Therapeutics common stock. This reflects both the exercised employee stock options and the open-market purchase completed on June 22, 2026.

What types of transactions are reported for Faeth Therapeutics (FTH) CEO in this Form 4?

The filing reports derivative exercises and an open-market purchase. Parikh exercised employee stock options to receive 53,465 common shares and made an open-market purchase of 2,806 common shares, all classified as acquisitions of Faeth Therapeutics stock.